Division of Blood Transfusion, Okayama University Hospital, Okayama, Japan.
Department of Hematology and Oncology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Transfusion. 2022 Sep;62(9):1829-1838. doi: 10.1111/trf.17039. Epub 2022 Aug 5.
For pediatric recipients, red blood cells (RBCs) are added to bone marrow (BM) collections before low RBC volume BM processing using COBE Spectra (COBE) or Spectra Optia (Optia). However, the processing efficiency of this approach has not been evaluated. This study aimed to evaluate RBC depletion and nucleated cell subpopulation recovery rates in third-party RBC-manipulated BM products processed with the COBE or Optia.
We retrospectively collected data on RBC depletion from low RBC volume BM with third-party RBCs (manipulated group) and on conventional large-volume, BM (unmanipulated group) processing performed between September 2010 and December 2021. All procedures were performed using COBE or Optia.
The median residual RBC volume in the manipulated group was 9.5 ml in COBE and 2.5 ml in Optia (p = .01). The median total nucleated cell (TNC) and mononuclear cell (MNC) were comparable between the manipulated groups using each cell separator (TNC, 40.8 vs. 47.1%; MNC, 78.3 vs. 79.4%). The manipulation did not adversely affect TNC and MNC recoveries in either device. In addition, Optia achieved similar CD34 cell recovery to that in large-BM-volume processing using the same device (147.5 vs. 184.5%, p = .112). During a follow-up period, neutrophil engraftment was achieved in all patients who received third-party RBC-manipulated grafts, and platelet engraftment was achieved in all cases, except one.
The addition of third-party RBC to low RBC volume BM collections from or for pediatric patients does not have any negative impact on either RBC depletion or hematopoietic cell recovery during processing with the widely used cell separator.
对于儿科受者，在使用 COBE Spectra（COBE）或 Spectra Optia（Optia）进行低红细胞体积 BM 处理之前，会向骨髓（BM）采集物中添加红细胞（RBC）。然而，这种方法的处理效率尚未得到评估。本研究旨在评估使用 COBE 或 Optia 处理第三方 RBC 处理的低 RBC 体积 BM 产品中的 RBC 耗竭和有核细胞亚群恢复率。
我们回顾性收集了 2010 年 9 月至 2021 年 12 月期间进行的低 RBC 体积 BM 与第三方 RBC（处理组）的 RBC 耗竭数据，以及常规大体积 BM（未处理组）的处理数据。所有程序均使用 COBE 或 Optia 进行。
在 COBE 中，处理组中剩余 RBC 体积的中位数为 9.5ml，在 Optia 中为 2.5ml（p=0.01）。在使用每种细胞分离仪时，处理组之间的总核细胞（TNC）和单核细胞（MNC）中位数均无差异（TNC，40.8%对 47.1%；MNC，78.3%对 79.4%）。该操作并未对两种设备中的 TNC 和 MNC 回收率产生不利影响。此外，Optia 在使用相同设备对大体积 BM 进行处理时，获得了与 CD34 细胞相似的回收率（147.5%对 184.5%，p=0.112）。在随访期间，接受第三方 RBC 处理的移植物的所有患者均实现了中性粒细胞植入，除 1 例外，所有患者均实现了血小板植入。
向来自或用于儿科患者的低 RBC 体积 BM 采集物中添加第三方 RBC，在使用广泛使用的细胞分离仪进行处理时，不会对 RBC 耗竭或造血细胞恢复产生任何负面影响。
